Physician profile
Ryan Schmidtz
NPI 1437492881
$524.33
in general payments reported to CMS, 2019-2025
12 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.89 · 2020: $19.15 · 2021: $66.56 · 2022: $65.63 · 2023: $112 · 2024: $88.83 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $120.14 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $64.27 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $62.42 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $57.76 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.85 | 2022-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $33.40 | 2023 | Qelbree |
| Bausch Health US, LLC | $29.55 | 2021-2022 | |
| Abbvie INC. | $28.70 | 2021-2023 | Vraylar |
| Merck Sharp & Dohme LLC | $23.73 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.08 | 2021 | |
| Noven Therapeutics, LLC | $17.53 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Schmidtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.